Rice Hall James & Associates, LLC Biomarin Pharmaceutical Inc Transaction History

Rice Hall James & Associates, LLC

  • $1.69 Billion
  • Q3 2024

A detailed history of Rice Hall James & Associates, LLC transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Rice Hall James & Associates, LLC holds 10,327 shares of BMRN stock, worth $678,070. This represents 0.04% of its overall portfolio holdings.

Number of Shares
10,327
Previous 20,679 50.06%
Holding current value
$678,070
Previous $1.7 Million 57.4%
% of portfolio
0.04%
Previous 0.11%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 28, 2024
SELL
$69.02 - $93.84 $714,495 - $971,431
-10,352 Reduced 50.06%
10,327 $725,000
Q2 2024

Aug 07, 2024
SELL
$74.43 - $92.22 $598,640 - $741,725
-8,043 Reduced 28.0%
20,679 $1.7 Million
Q1 2024

Apr 23, 2024
SELL
$83.81 - $99.0 $57,996 - $68,508
-692 Reduced 2.35%
28,722 $2.51 Million
Q4 2023

Feb 08, 2024
SELL
$76.22 - $98.51 $110,747 - $143,135
-1,453 Reduced 4.71%
29,414 $2.84 Million
Q3 2023

Nov 02, 2023
SELL
$85.07 - $94.48 $154,657 - $171,764
-1,818 Reduced 5.56%
30,867 $2.73 Million
Q2 2023

Jul 24, 2023
SELL
$86.68 - $100.3 $117,364 - $135,806
-1,354 Reduced 3.98%
32,685 $2.83 Million
Q1 2023

May 11, 2023
SELL
$87.74 - $117.27 $32,376 - $43,272
-369 Reduced 1.07%
34,039 $3.31 Million
Q4 2022

Jan 27, 2023
BUY
$80.93 - $108.63 $1.08 Million - $1.45 Million
13,377 Added 63.61%
34,408 $0
Q3 2022

Nov 01, 2022
SELL
$82.16 - $96.94 $2.38 Million - $2.81 Million
-28,972 Reduced 57.94%
21,031 $1.78 Million
Q2 2022

Aug 08, 2022
SELL
$71.48 - $86.85 $676,701 - $822,208
-9,467 Reduced 15.92%
50,003 $4.14 Million
Q1 2022

May 05, 2022
SELL
$74.28 - $92.69 $152,496 - $190,292
-2,053 Reduced 3.34%
59,470 $4.59 Million
Q4 2021

Feb 14, 2022
SELL
$71.72 - $91.47 $466,323 - $594,737
-6,502 Reduced 9.56%
61,523 $5.44 Million
Q3 2021

Nov 09, 2021
SELL
$74.77 - $85.47 $333,922 - $381,709
-4,466 Reduced 6.16%
68,025 $5.26 Million
Q2 2021

Jul 29, 2021
SELL
$75.51 - $84.79 $1,057 - $1,187
-14 Reduced 0.02%
72,491 $6.05 Million
Q1 2021

May 14, 2021
SELL
$74.73 - $90.69 $242,349 - $294,107
-3,243 Reduced 4.28%
72,505 $5.48 Million
Q4 2020

Feb 16, 2021
SELL
$72.61 - $90.2 $372,126 - $462,275
-5,125 Reduced 6.34%
75,748 $6.64 Million
Q3 2020

Nov 16, 2020
BUY
$71.87 - $131.03 $718,053 - $1.31 Million
9,991 Added 14.1%
80,873 $6.15 Million
Q2 2020

Aug 14, 2020
SELL
$79.55 - $124.22 $84,004 - $131,176
-1,056 Reduced 1.47%
70,882 $8.74 Million
Q1 2020

May 15, 2020
SELL
$71.37 - $96.85 $35,042 - $47,553
-491 Reduced 0.68%
71,938 $6.08 Million
Q4 2019

Jan 29, 2020
BUY
$64.27 - $86.37 $434,658 - $584,120
6,763 Added 10.3%
72,429 $6.12 Million
Q3 2019

Oct 30, 2019
SELL
$67.4 - $85.11 $46,169 - $58,300
-685 Reduced 1.03%
65,666 $4.43 Million
Q2 2019

Aug 01, 2019
SELL
$80.35 - $93.9 $993,608 - $1.16 Million
-12,366 Reduced 15.71%
66,351 $5.68 Million
Q1 2019

May 01, 2019
BUY
$84.2 - $98.62 $811,435 - $950,400
9,637 Added 13.95%
78,717 $6.99 Million
Q4 2018

Feb 14, 2019
BUY
$80.14 - $106.07 $1.33 Million - $1.76 Million
16,609 Added 31.65%
69,080 $5.88 Million
Q3 2018

Oct 25, 2018
BUY
$93.92 - $105.72 $112,422 - $126,546
1,197 Added 2.33%
52,471 $5.09 Million
Q2 2018

Aug 02, 2018
BUY
$76.01 - $99.03 $677,477 - $882,654
8,913 Added 21.04%
51,274 $4.83 Million
Q1 2018

Apr 25, 2018
BUY
$77.67 - $92.63 $99,805 - $119,029
1,285 Added 3.13%
42,361 $3.43 Million
Q4 2017

Jan 23, 2018
BUY
$80.76 - $95.13 $2.61 Million - $3.08 Million
32,371 Added 371.87%
41,076 $3.66 Million
Q3 2017

Oct 30, 2017
BUY
$80.6 - $94.95 $701,623 - $826,539
8,705
8,705 $810,000

Others Institutions Holding BMRN

# of Institutions
637
Shares Held
177M
Call Options Held
2.01M
Put Options Held
1.28M
View Full List

About BIOMARIN PHARMACEUTICAL INC

BMRN Quotes by TradingView
  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $12.2B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Rice Hall James & Associates, LLC Portfolio

Follow Rice Hall James & Associates, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rice Hall James & Associates, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rice Hall James & Associates, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email